Professionals

Clinical Research Projects

Agent(s) Protocol PI(s)
18F-FAZA DX-FAZ-001: A Phase I/II Imaging Study of 1-a-D-(5-deoxy-5-18F-fluoroarabinofuranosyl)-2-nitroimidazole(18F-FAZA) in Patients with Known Squamous Cell Carcinoma of the Head & Neck, Small Cell & Non-Small Cell Carcinoma of the Lung, Lymphoma, Glioblastoma Multiforme, Neuroendocrine Tumours or Renal Cell Carcinoma Dr. A.J.B. McEwan
18F-FAZA PK-FAZ-003: A Radiopharmacokinetic and Radiodosimetric Phase I Imaging Study of 1-a-D-(5-deoxy-5-18F-fluoroarabino-furanosyl)-2-nitroimidazole (18F-FAZA) Dr. A.J.B. McEwan
18F-FAZA, FluGlucoScan® Injection KT-FAZ-004: A Phase II Pre-operative Hypoxia PET Imaging Study using 18F-FAZA in Patients with Invasive Duct Carcinoma of the Breast Dr. A.J.B. McEwan, Dr. K. Tonkin
18F-FAZA, FluGlucoScan® Injection CS-FAZ-005: A Pilot Study of the Role of 18F-FAZA in Assessing Early Functional Response in Patients with Inoperable Non-Small Cell Lung Cancer Undergoing Radiotherapy or Chemo-radiotherapy Dr. W. Roa
18F-FAZA IGAR 2007116: Diffusion Weighted Magnetic Resonance and 18F-FAZA PET Imaging in Predicting Response to Neo-adjuvant Chemo-Radiotherapy in Oesophageal Carcinoma Dr. K. Joseph
18F-FES, FluGlucoScan® Injection For Women with Estrogen Positive Metastatic Breast Cancer Discordance of Pre-Treatment FDG-PET and FES-PET in Addition to Presence of Ki-67 and Human Epidermal Growth Factor 2 (Her-2) Overexpression will Predict for Hormone Refractory Disease When Compared to Standard Response Criteria Dr. K. Tonkin
18F-FLT DX-FLT-001: An Imaging Pilot Study of 18F-fluoro-3′-deoxy-3′-L-fluorothymidine (18F-FLT) in Patients with Locally Advanced or Metastatic Pancreatic Cancer who will be Treated with Gemcitabine Dr. A.J.B. McEwan, Dr. M. Sawyer
18F-FLT DX-FLT-002: A Contiguous, Sequential Phase I/II Imaging Study of 18F-fluoro-3′-deoxy-3′-L-fluorothymidine (18F-FLT) in Patients with Known or Suspected Carcinoma of the Lung, Breast, Renal Cell, Pancreas, or Brain, and with Gastrointestinal Malignancies, Neuroendocrine Tumours or Lymphoma Dr. A.J.B. McEwan
18F-FLT CA191005: A Phase I Multiple Ascending Dose Study of BMS-754807 in Combination with Paclitaxel and Carboplatin in Subjects with Advanced or Metastatic Solid Tumors Dr. Q.S.C. Chu
Na18F DX-FLU-001: An Observational Pilot Study of 18F-Sodium Fluoride (Na18F) Whole Body PET Scans in Patients for whom 99mTc MDP Bone Scans Would Normally be Indicated Dr. K. Gulenchyn, Dr. A.J.B. McEwan
11C-Choline JA-CHO-002: A Feasibility Study to Evaluate 11C-Choline PET Scans for Image-guided Helical Tomotherapy Boost on Dominant Intraprostatic Lesions and as a Predictive Factor for Biochemical Disease-Free survival in Patients with Localized Prostate Cancer Treated with External Beam Radiotherapy Dr. J. Amanie, Dr. A.J.B. McEwan
11C-Choline BIAS: Biological Investigations in Active Surveillance Dr. N. Usmani
11C-DTBZ Neuroanatomical Correlates of Gait and Balance Impairment in Parkinson’s Disease Dr. W. Martin
CPERT, GPERT DX-CPERT-001: A Phase I Study of Cyclotron-produced Tc-99m Pertechnetate (CPERT) in Patients with Thyroid Cancer Dr. A.J.B. McEwan

Studies using FluGlucoScan® Injection

Sponsor Site / Site PI Study Title / Description
AHS / Berlex CCI / Andrew Belch Efficacy and safety of treatment with a single dose of Y-90 ibritumomabtiuzetan in patients with previously untreated low tumour burden indolent non-Hodgkin’s lymphoma
Berlex CCI / Andrew Belch Phase III randomized sequential study to evaluate efficacy and safety of treatment with the Zevalin study regimen vs. observation in patients with diffuse large B-cell lymphoma in remission after 1st line CHOP-rituximab treatment
NCIC CCI / Wilson Roa Phase II study of Accelerated Hypofractionated 3DCRT for Inoperable Stage I/II NSCLC
Eisai Medical Research Inc. CCI / Michael Sawyer Phase II study of efficacy, safety and biomarkers of activity of E7820 + Cetuximab in patients with colorectal cancer preceded by a run-in study to determine safety on the combination in advanced solid tumours
Merck CCI / CharlesButts START: Phase III study of the cancer vaccine Stimuvax in NSCLC patients with unresectable stage III disease
Osmosis Research CCI / Charles Butts Phase II study of Chemoradiation for Locally Advanced and Low Rectal carcinoma: Avastatin-Capecitabine-Oxaliplatin-Radiation Rectal Cancer Trial (A-CORRECT)
AHS AHS / Peter Venner A phase I open-labeled, single-arm, dose escalation, clinical and pharmacology study of dichloroacetate (DCA) in patients with recurrent and/or metastatic solid tumours
Unknown UAH / unknown Phase II Open-Labeled, Single Arm Clinical and Pharmacology Study of Dichloroacetate (DCA) in Patients with Recurrent and/or Metastatic Breast, Non-small Cell Lung and Colorectal Cancers
Celgene CCI / Andrew Belch Phase II study to evaluate the safety and efficacy of lenalidomide in combination with dexamethasone in subjects with relapsed Refractory Diffuse Large B-cell Lymphoma
NovaRx Corp. CCI / Quincy Chu Phase III, Lucanix, randomized, double-blind, placebo-controlled trial for stages II/IV NSCLC (responded/stable patients), platinum-based combination chemo
AHS CCI / Wilson Roa Phase I/II dose escalation trial using hypofraction with individualized differential boosting with respiratory gated intensity-modulated radiation therapy (IMRT) in the treatment of NSCLC
AHS CCI / Katia Tonkin For Women with Estrogen Positive Metastatic Breast Cancer Discordance of Pre-Treatment FDG-PET and FES-PET in Addition to Presence of Ki-67 and Human Epidermal Growth Factor 2 (Her-2) Overexpression will Predict for Hormone Refractory Disease When Compared to Standard Response Criteria
Unknown HSC / Daniel Levin [18F]-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography (PET) in Pediatric Oncology
Unknown FMC / Reinhard Kloiber A Phase II Study of 18F-Fluorodeoxyglucose (FluGlucoScan™) in Adults with Cancer or Suspected Cancer using PET/CT
Hoffmann La Roche Ltd. FMC / Unknown A single-arm, open-label, multicentre Phase Ib feasibility trial of bevacizumab given in combination with concomitant chemoradiation (cisplatin and vinorelbine) in locally advanced unresectale non-squamous, non-small cell lung cancer
Hoffmann La Roche Ltd. FMC / Unknown An open label study to determine the effect of R1507 (RO4858696) plus Tarceva (erlotinib) on progression-free survival in patients with stage IIIB/IV non-small cell lung cancer (NSCLC) with progressive disease after clinical benefit to second or third line erlotinib monotherapy
Schering-Plough Canada Inc. UAH / Sunil Desai; HSC / unknown A study to determine the activity of SCH 717454 in subjects with osteosarcoma or Ewing’s sarcoma that has relapsed after standard systemic therapy
COG UAH / Paul Grundy A Phase II study of bertezomib (Velcade, PS-341, IND #58443) in combination with ifosfamide/vinorelbine in pediatric patients and young adults with refractory/recurrent Hodgkin’s disease
BCCA BCCA / Don Wilson; HSC / unknown [18F]-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography (PET) in Pediatric Oncology
COG FMC / Douglas Strother; HSC / Rochelle Yanofsky UAH / Sunil Desai A phase II study of weekly gemcitabine and vinorelbine in children with recurrent or refractory Hodgkin’s disease
COG Same as previous A phase III study of dose-intensive, response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate risk Hodgkin’s disease
COG Same as previous Phase III study for the treatment of children and adolescents with newly diagnosed low-risk Hodgkin’s disease
COG Same as previous A pilot study of re-induction chemotherapy with ifosfamide and vinorelbine (IV) in children with refractory/relapsed Hodgkin’s disease
COG Same as previous Treatment of children with newly-diagnosed low stage lymphocyte predominant Hodgkin’s disease (LPHD)
COG Same as previous A phase III trial of treatment of advanced-stage anaplastic large cell lymphoma (ALCL) with standard APO (doxorubicin, prednisone, vincristine) versus consolidation with a regimen including vinblastine
COG Same as previous A phase II study of the combination of cyclophosphamide, prednisone and rituximab (CPR) in children, adolescents and young adults with CD20 positive post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation (SOT)
COG Same as previous A pilot study to determine the toxicity of the addition of rituximab to the induction and consolidation phases and the addition of rasburicase to the reduction phase in children with newly diagnosed advanced B-cell leukemia/lymphoma treated with LMB/FAB therapy
COG Same as previous A randomized phase III study for the treatment of newly diagnosed disseminated lymphoblastic lymphoma or localized lymphoblastic lymphoma
COG Same as previous Randomized study of vincristine, dactinomycin and cyclophosphamide (VAC) versus VAC alternating with vincristine and irinotecan (VI) for patients with intermediate-risk rhabdomyosarcoma (RMS)
Hoffman La Roche FMC / Douglas Stewart FDG-PET-Stratified R-DICEP and R-BEAM/ASCT for diffuse large B-cell lymphoma
Bristol-Myers Squibb Canada CCI / Michael Sawyer, Quincy Chu Phase I multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of BMS 833923 in combination with Carboplatin and Etoposide followed by BMS alone in subjects with extensive stage small cell lung cancer
Novartis CCI / Quincy Chu Phase II multicentre, open label study of AUY922 administered IV on a once-weekly schedule in patients with advanced NSCLC who have received at least two lines of prior chemotherapy
Eli Lilly CCI / Michael Smylie Phase III clinical study of Pemetrexed, Cisplatin, and RT followed by Consolidation Pemetrexed vs. Etoposide, Cisplatin and RT followed by Consolidation Cytotoxic Chemotherapy of choice in patients with unresectable, locally advanced, stage 3 NSCLC other than predominantly squamous cell histology
Pfizer CCI / Anil Joy, Quincy Chu Phase III randomized, open label study of the efficacy and safety of Crizotinib vs. Pemetrexed/Cisplatin or Pemetrexed/Carboplatin in previously untreated patients with non squamous carcinoma of the lung harbouring a translocation or inversion event involving the anaplastic lymphoma kinase ALK gene locus
Sanofi Aventis CCI, Charlie Butts Randomized Phase III trial of Gemcitabine/Carboplatin with or without Iniparib (SAR240550) (a PARP1 inhibitor) in subjects with previously untreated stage 4 NSCLC
Roche CCI, Randeep Sangha Phase III, open label, randomized study in previously untreated patients with advanced indolent non-Hodgkin’s lymphoma evaluating the benefit of GA101 (R05072759) plus chemotherapy compared
Roche CCI, Neil Chua Phase III, open label, randomized trial comparing the efficacy of GA101 (05072759) in combination with CHOP (G-CHOP) vs. rituximab and CHOP (R-CHOP) in previously untreated patients with CD20-positive diffuse large B-cell lymphoma